Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-10-25
2005-10-25
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S326000, C514S341000, C514S361000, C514S365000, C514S374000, C514S397000, C514S406000, C544S405000, C548S127000, C548S200000, C548S236000, C548S312400, C548S364100, C548S365700, C548S375100, C546S211000, C546S275400
Reexamination Certificate
active
06958339
ABSTRACT:
The present invention is directed to drugs, in particular, pyrazole derivatives represented by the following general formula (I)which have a calcium release-activated calcium channel inhibitory effect and medicinal compositions, in particular, calcium release-activated calcium channel inhibitors containing the above compounds as the active ingredient, wherein each substituent is defined in the specification.The present invention also relates to a pharmaceutical composition containing an effective amount of the compound of formula (I) and a pharmaceutically effective carrier.The present invention further relates to methods of treatment of diseases associated with calcium release-activated calcium channels, diseases associated with IL-2 production, and methods of treatment of allergic, inflammatory or auto-immune diseases.
REFERENCES:
patent: 4728653 (1988-03-01), Campbell et al.
patent: 5403838 (1995-04-01), Reinhard et al.
patent: 5571821 (1996-11-01), Vitukudi et al.
patent: 5712279 (1998-01-01), Biller et al.
patent: 6140509 (2000-10-01), Behan et al.
patent: 6506747 (2003-01-01), Betageri et al.
patent: 2001/0044445 (2001-11-01), Bamaung et al.
patent: 2249542 (1999-04-01), None
patent: 34 01 911 (1985-01-01), None
patent: 64-55557 (1989-03-01), None
patent: 1-287071 (1989-11-01), None
patent: 03-77869 (1991-04-01), None
patent: 3-141261 (1991-06-01), None
patent: 4-234851 (1992-08-01), None
patent: 10-72434 (1998-03-01), None
patent: WO 85/04878 (1985-11-01), None
patent: WO 96/10559 (1996-04-01), None
patent: WO 96/23783 (1996-08-01), None
patent: WO 96/31517 (1996-10-01), None
patent: WO 97/05131 (1997-02-01), None
patent: WO 98/37068 (1998-08-01), None
patent: 99/51580 (1999-10-01), None
patent: 99/62885 (1999-12-01), None
Cacchi et al., CAPLUS Abstract 127:293164 (Synlett (1997), (8), 959-961), 1997.
Sykulski et al., CAPLUS Abstract 91:74524, 1979.
Putney, Jr. et al., Mechanisms of capacitative calcium entry, Journal of Cell Science, 114(12), pp. 2223-2229, 2001.
McDyer et al., IL-2 Recepto Blockade Inhibits Late, But not early, IFN-g and CD40 Ligand Expression, The Journal of Immunology, 169: 2736-46, 2002.
Elgert, Autoimmunity, Immunology: Understanding the Immune System, pp. 315-330, 1996.
Wachlin et al., IL-1b, IFN-1g and TNF-a increase vulnerability of pancreatic beta cells to autoimmune destruction, Journal of Autoimmunity, 20, pp. 303-312, 2003.
Bremner et al., Therapy of Crohn's Disease in childhood, Expret Opin. Pharmacother. 3(7):809-825, 2002.
Singh et al., Immune Therapy in inflammatory bowel disease and models of colitis, British Journal of Surgery, 88, 1558-1569, 2001.
Robinson, Medical Therapy of Inflammatory Bowel Disease for the 21stCentury, Eur. J. Surg. Suppl. 582:90-98, 1998.
Beers et al., Crohn's Disease, Ulcerative colitis, The Merck Manual of Diagnosis and Therapy, Seventeenth Edition (online), 1999.
Patel et al., Synthesis of substituted 6-(3′,5′-dimethyl-1H-pyrazol-1′-yl)quinolines and evaluation of their biological activities, Indian Journal of Chemistry, vol. 29B, pp. 836-842, Sep. 1990.
Finar et al., Chem. Abstract 55:25921f, 1961.
Bouchet et al., Chem. Abstract 85:5545w, 1976.
Patel et al., Chem. Abstract 114:23862u, 1991.
Kawamura et al., Chem. Abstract 128:230375, 1998.
Mizukawa et al., Chem. Abstract 111:205323, 1989.
Bartroli et al,J. Med. Chem., 41(11):1855-1868 (1998).
Wright et al,J. Med. Chem., 7(1):102-105 (1964).
Okazaki, “Nonlinear Optical Material and Triazole Compound”, Chemical Abstract No. 325369, vol. 123, No. 24 (Dec. 11, 1995).
Nicolai et al,Chem. Pharm. Bull., 42(8):1617-1630 (1994).
Badachikar et al,Indian J. Chem.., 25B:1079-1080 (1996).
Mokhtar et al,Pharmazie, 33(10):649-651 (1978).
Funatsu Masashi
Ishikawa Jun
Kawazoe Souichirou
Kubota Hirokazu
Sugasawa Keizo
Astellas Pharma Inc.
Rao Deepak
LandOfFree
Pyrazole derivative does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrazole derivative, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrazole derivative will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3485225